Short Interest in Atossa Therapeutics, Inc. (NASDAQ:ATOS) Expands By 17.0%

Atossa Therapeutics, Inc. (NASDAQ:ATOS) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 12,350,000 shares, a growth of 17.0% from the March 31st total of 10,560,000 shares. Based on an average daily volume of 1,620,000 shares, the short-interest ratio is currently 7.6 days.

Insider Buying and Selling

In other Atossa Therapeutics news, Director Jonathan Finn bought 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 10th. The stock was acquired at an average price of $1.77 per share, with a total value of $44,250.00. Following the completion of the purchase, the director now directly owns 25,000 shares of the company’s stock, valued at approximately $44,250. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Atossa Therapeutics stock. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 133,591 shares of the company’s stock, valued at approximately $98,000. Connor Clark & Lunn Investment Management Ltd. owned about 0.11% of Atossa Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 12.74% of the company’s stock.

Atossa Therapeutics Trading Up 0.7 %

Atossa Therapeutics stock traded up $0.01 during mid-day trading on Friday, reaching $1.53. The stock had a trading volume of 900,111 shares, compared to its average volume of 2,648,768. Atossa Therapeutics has a fifty-two week low of $0.59 and a fifty-two week high of $2.31. The stock’s 50-day simple moving average is $1.44 and its 200-day simple moving average is $1.02.

Atossa Therapeutics (NASDAQ:ATOS) last announced its earnings results on Monday, April 1st. The company reported ($0.06) earnings per share (EPS) for the quarter. As a group, equities analysts anticipate that Atossa Therapeutics will post -0.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on ATOS. HC Wainwright reissued a “buy” rating and issued a $4.00 price objective on shares of Atossa Therapeutics in a research note on Tuesday, April 16th. StockNews.com cut Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, March 18th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Atossa Therapeutics in a research note on Friday, January 12th.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.